A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

NCT01793649 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis
Chronic Obstructive Pulmonary Disease

Interventions

DRUG: GS-5737

Sponsor

Gilead Sciences